(BUSINESS WIRE)–Jan. 20, 2015– ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the European Commission (EC) has endorsed the final opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) on Iclusig® (ponatinib) following recommendations made by the Pharmacovigilance Risk Assessment Committee (PRAC). This concludes the European Article 20 review of Iclusig and is a binding decision for Iclusig to continue to be prescribed in Europe in… Read more »

Shares of Ariad Pharmaceuticals closed last Friday at $6.24 . ARIA has a 1-year high of $9.83 and a 1-year low of $4.90. The stock’s 50-day moving average is $6.79 and it’s 200-day moving average is $6.09.

In total, one research analyst has rated the stock with a Sell rating, one research analyst has assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $6.24 which is -1.1% under where the stock closed last Friday.

Ariad Pharmaceuticals Inc is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.